GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aion Therapeutic Inc (XCNQ:AION) » Definitions » Net-Net Working Capital

Aion Therapeutic (XCNQ:AION) Net-Net Working Capital : C$-0.01 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aion Therapeutic Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Aion Therapeutic's Net-Net Working Capital for the quarter that ended in Jan. 2024 was C$-0.01.

The industry rank for Aion Therapeutic's Net-Net Working Capital or its related term are showing as below:

XCNQ:AION's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.44
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Aion Therapeutic Net-Net Working Capital Historical Data

The historical data trend for Aion Therapeutic's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aion Therapeutic Net-Net Working Capital Chart

Aion Therapeutic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Net-Net Working Capital
Get a 7-Day Free Trial - -0.02 -0.01 -0.02 -0.02

Aion Therapeutic Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.01 -0.01

Competitive Comparison of Aion Therapeutic's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aion Therapeutic's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Price-to-Net-Net-Working-Capital falls into.



Aion Therapeutic Net-Net Working Capital Calculation

Aion Therapeutic's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Apr. 2023 is calculated as

Net-Net Working Capital(A: Apr. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0+0.75 * 0+0.5 * 0-2.936
-0-0)/147.299
=-0.02

Aion Therapeutic's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jan. 2024 is calculated as

Net-Net Working Capital(Q: Jan. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.349+0.75 * 0.059+0.5 * 0.4-4.855
-0-0)/411.549
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Aion Therapeutic  (XCNQ:AION) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Aion Therapeutic Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Aion Therapeutic's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Aion Therapeutic (XCNQ:AION) Business Description

Traded in Other Exchanges
Address
700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery.
Executives
Ismail Abdul Fattah Director or Senior Officer of 10% Security Holder

Aion Therapeutic (XCNQ:AION) Headlines

No Headlines